Correction: Propylthiouracil prevents cutaneous and pulmonary fibrosis in the reactive oxygen species murine model of systemic sclerosis

Correction

After publication of our recent article [1], we noticed that Figure 2A was incorrect as a result of mislabeling of the image files. The correct Figure 2 is given in full here as Figure 1.

Figure 1.

Immunostaining for α-SMA in cutaneous samples. Representative tissue sample from: (A) Sham animal; (B) HOCl mice; (C) HOCl + PTU animal (original magnification, ×40). The arrows show strong diffuse staining of myofibroblast nuclei (dark brown staining). (D) Number of myofibroblasts from the three experimental groups (HOCl + PTU group, n = 10; HOCl group, n = 10; Sham, n = 5). The increase of myofibroblast population in the skin of HOCl mice is prevented by propylthiouracil administration. Values are expressed as the mean and standard deviation. *P <0.001 versus Sham; #P <0.001 versus HOCl. α-SMA, alpha-smooth muscle actin; HOCl, hypochlorous acid; HPF, high-powered field; PTU, propylthiouracil.

Competing interests

The authors declare that they have no competing interests.

See related research by Bagnato et al., http://arthritis-research.com/content/15/5/R120